ResMed (NYSE: RMD) Stock Gains Momentum Amidst Strong Analyst Ratings

Font: Financial Modeling Prep  • Jul 02, 2026

• Investment bank Goldman Sachs confirmed a "Buy" rating for ResMed (NYSE: RMD) and added the medical equipment stock to its APAC Conviction List.
• Zacks Investment Research upgraded ResMed to a Zacks Rank #2 (Buy), suggesting expected earnings improvement and potential stock value appreciation.
• Wall Street analysts project a mean price target of $249.86 for ResMed, indicating a potential upside of 28.2%, with shares gaining 6.6% over the past four weeks.

ResMed is a global medical equipment company specializing in developing and selling devices and software for treating sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. The company provides cloud-connected devices that help patients and doctors manage these long-term health issues from home, highlighting its focus on patient management solutions.

On July 1, 2026, investment bank Goldman Sachs confirmed its "Buy" rating for ResMed. At the time of this announcement, the stock's price was $201.10. As highlighted by TheFly, Goldman Sachs also added the company to its APAC Conviction List, which includes stocks the bank strongly believes will perform well, signaling strong analyst confidence.

This positive view is shared by others. Zacks Investment Research recently upgraded ResMed to a Zacks Rank #2 (Buy). This type of analyst upgrade often suggests that analysts expect the company's earnings to improve, which can signal a potential rise in the stock's value in the near future, making it a noteworthy investment opportunity.

Wall Street analysts have a mean price target of $249.86 for ResMed, which indicates a potential upside of 28.2%. This average is based on 14 different short-term price targets from analysts. These targets range from a low of $180 to a high of $321, showing varied but generally positive market expectations for the RMD stock.

Reflecting this optimism, shares of ResMed have gained 6.6% over the past four weeks. The stock is currently trading at $201.10, with a market capitalization of $29.17 billion. Over the last 52 weeks, the stock has traded between a low of $180.27 and a high of $293.81, demonstrating its recent stock performance and trading range.